ArticlePloS one2014
Subcutaneous immunization with inactivated bacterial components and purified protein of Escherichia coli, Fusobacterium necrophorum and Trueperella pyogenes prevents puerperal metritis in Holstein dairy cows.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 81 citations in OpenAlex.
- Virulence factors and therapeutic methods ofVirulence · 2025Review
- Further delineation of the etiology of liver abscesses in cattle and indication of hindgut as a potential source of pathogens.Microbiology spectrum · 2025Article
- Investigating the Effects of Flunixin Meglumine and Meloxicam on Humoral Immune Responses AgainstArchives of Razi Institute · 2025Article
- Reanalysis of 2 metritis studies demonstrates different patterns of postpartum uterine infection for primiparous versus multiparous cows.JDS communications · 2025Article
- InactivatedFrontiers in immunology · 2025Article
- Uterine Disease in Dairy Cows: A Comprehensive Review Highlighting New Research Areas.Veterinary sciences · 2024Review
- Construction of live-attenuated Trueperella pyogenes by antibiotic treatment and sequential passage: methods for vaccine development.Archives of microbiology · 2023Article
- Comparative Genome Analysis of 19Antibiotics (Basel, Switzerland) · 2022Article
- Investigation of antimicrobial susceptibility and virulence factor genes inFood science & nutrition · 2021Article
- Evaluation of Immunoprotective Effects ofFrontiers in veterinary science · 2021Article
- Recent advances and future directions for uterine diseases diagnosis, pathogenesis, and management in dairy cows.Animal reproduction · 2020Review
- Vaginal bacterial community composition and concentrations of estradiol at the time of artificial insemination in Brangus heifers.Journal of animal science · 2020Article
- Evaluation of the Potency of Two Pyolysin-Derived Recombinant Proteins as Vaccine Candidates ofVaccines · 2020Article
- Salpingitis Impairs Bovine Tubal Function and Sperm-Oviduct Interaction.Scientific reports · 2019Article
- Pathogenicity and Virulence ofInternational journal of molecular sciences · 2019Review
- Tolerance and Innate Immunity Shape the Development of Postpartum Uterine Disease and the Impact of Endometritis in Dairy Cattle.Annual review of animal biosciences · 2019Review
- Characterisation of peripheral blood mononuclear cell populations in periparturient dairy cows that develop metritis.Veterinary immunology and immunopathology · 2018Article
- Blood as a route of transmission of uterine pathogens from the gut to the uterus in cows.Microbiome · 2017Article
- Complete Genome Sequence of vB_EcoM-UFV13, a New Bacteriophage Able To Disrupt Trueperella pyogenes Biofilm.Genome announcements · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study we evaluate the efficacy of five vaccine formulations containing different combinations of proteins (FimH; leukotoxin, LKT; and pyolysin, PLO) and/or inactivated whole cells (Escherichia coli, Fusobacterium necrophorum, and Trueperella pyogenes) in preventing postpartum uterine diseases. Inactivated whole cells were produced using two genetically distinct strains of each bacterial species (E. coli, F. necrophorum, and T. pyogenes). FimH and PLO subunits were produced using recombinant protein expression, and LKT was recovered from culturing a wild F. necrophorum strain. Three subcutaneous vaccines were formulated: Vaccine 1 was composed of inactivated bacterial whole cells and proteins; Vaccine 2 was composed of proteins only; and Vaccine 3 was composed of inactivated bacterial whole cells only. Two intravaginal vaccines were formulated: Vaccine 4 was composed of inactivated bacterial whole cells and proteins; and Vaccine 5 was composed of PLO and LKT. To evaluate vaccine efficacy, a randomized clinical trial was conducted at a commercial dairy farm; 371 spring heifers were allocated randomly into one of six different treatments groups: control, Vaccine 1, Vaccine 2, Vaccine 3, Vaccine 4 and Vaccine 5. Late pregnant heifers assigned to one of the vaccine groups were each vaccinated twice: at 230 and 260 days of pregnancy. When vaccines were evaluated grouped as subcutaneous and intravaginal, the subcutaneous ones were found to significantly reduce the incidence of puerperal metritis. Additionally, subcutaneous vaccination significantly reduced rectal temperature at 6±1 days in milk. Reproduction was improved for cows that received subcutaneous vaccines. In general, vaccination induced a significant increase in serum IgG titers against all antigens, with subcutaneous vaccination again being more effective. In conclusion, subcutaneous vaccination with inactivated bacterial components and/or protein subunits of E. coli, F. necrophorum and T. pyogenes can prevent puerperal metritis during the first lactation of dairy cows, leading to improved reproduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.